Patritumab
| Patritumab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | Intravenous |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | Investigational |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Patritumab is an experimental monoclonal antibody designed for the treatment of cancer. It specifically targets and binds to the human epidermal growth factor receptor 3 (HER3), which is involved in the proliferation and survival of certain types of cancer cells. Patritumab is being investigated for its potential use in treating various types of solid tumors, including breast cancer, non-small cell lung cancer (NSCLC), and head and neck cancer.
Development and Mechanism
Patritumab was developed by Daiichi Sankyo, a global pharmaceutical company. The drug operates by targeting HER3, a member of the epidermal growth factor receptor (EGFR) family, which also includes EGFR, HER2, and HER4. These receptors are tyrosine kinases that play critical roles in signaling pathways that regulate cell growth and survival. HER3 is known to be overexpressed in many cancers and is associated with poor prognosis and resistance to existing therapies.
By binding to HER3, patritumab inhibits its interaction with other members of the EGFR family, particularly HER2, thereby blocking the signaling pathways that lead to tumor growth and survival. This mechanism of action makes it a potential therapeutic option in cancers where HER3 plays a significant role.
Clinical Trials
Patritumab has been evaluated in several clinical trials. Early-phase trials have assessed its safety, tolerability, and preliminary efficacy in patients with advanced solid tumors. The results from these trials have provided the basis for further investigation in more targeted patient populations.
One of the notable Phase II trials involved patritumab in combination with erlotinib in patients with NSCLC. However, the study did not meet its primary endpoint of improved progression-free survival compared to erlotinib alone. Despite this, research continues to explore patritumab's potential in different combinations and settings.
Future Directions
Research is ongoing to better understand the role of HER3 in cancer and to optimize the therapeutic strategies involving patritumab. This includes the development of biomarkers to identify patients who are most likely to benefit from HER3-targeted therapies and the investigation of combination therapies that might overcome resistance mechanisms.
See Also
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
